Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Small Interfering Ribonucleic Acid (RNA) Market Value Growth And Long-Term Outlook
The small interfering ribonucleic acid (rna) market size has experienced significant expansion recently. It is forecast to increase from $18.86 billion in 2025 to $22.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 20.3%. The market’s past growth can be ascribed to progress in molecular biology research, a rise in genetic and chronic disease prevalence, early achievements of rna-based therapies, greater investment in genomics research, and the elucidation of rna interference mechanisms.
The small interfering ribonucleic acid (rna) market is projected to experience substantial growth over the coming years, reaching $47.07 billion by 2030, driven by a compound annual growth rate (CAGR) of 20.0%. This anticipated expansion is fueled by factors such as the rise in regulatory clearances for RNA-based therapies, an increasing need for personalized medical treatments, advancements in nanoparticle delivery systems, heightened investment from pharmaceutical firms, and the wider use of siRNA in addressing infectious and rare diseases. Key developments during this period are expected to involve the greater clinical acceptance of RNA interference therapies, an intensified focus on gene silencing techniques, the proliferation of sophisticated siRNA delivery platforms, increased funding for the development of precision therapeutics, and a stronger emphasis on scalable RNA production.
Get A Free Sample Report With In-Depth Market Insights:
Small Interfering Ribonucleic Acid (RNA) Market Growth Momentum: What Factors Are Shaping Demand?
The escalating need for personalized medicine is projected to fuel the expansion of the small interfering ribonucleic acid (RNA) market in the future. This medical strategy customizes treatments for individual patients, considering their genetic makeup, environmental influences, and lifestyle choices, thereby enhancing results and quality of care. The growing need for personalized medicine stems from progress in genomic technologies, allowing for the accurate detection of genetic variations and the creation of customized treatments for specific individuals. Small interfering ribonucleic acid (siRNA) contributes to personalized medicine through its capacity for targeted gene silencing, positioning it as an effective option for addressing particular genetic conditions and illnesses. By precisely blocking disease-causing mRNA, it minimizes unintended effects, leading to improved therapeutic effectiveness and better patient results. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) granted approval to 26 novel personalized medicines in 2023, marking a considerable rise from the 12 approved in 2022. Consequently, the increased demand for personalized medicine is serving as a primary catalyst for the expansion of the small interfering ribonucleic acid (RNA) market.
Small Interfering Ribonucleic Acid (RNA) Market Segment Performance And Emerging Opportunities
The small interfering ribonucleic acid (rna) market covered in this report is segmented –
1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery
Small Interfering Ribonucleic Acid (RNA) Market Trends Redefining Industry Growth
Major companies engaged in the small interfering ribonucleic acid (siRNA) therapeutics market are prioritizing the acquisition of regulatory authorizations for new mechanisms to treat rare genetic diseases, aiming to deliver sustained effects and reduce the frequency of administration for patients. Regulatory approvals are formal clearances issued by authorities, allowing a drug or therapy to be safely evaluated, commercialized, or utilized in patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), which stands as the first small interfering ribonucleic acid (siRNA)-based treatment for adults and adolescents aged 12 years and older diagnosed with hemophilia A or B, regardless of inhibitor status. It is designed to lower antithrombin levels, thereby enhancing thrombin generation to promote clot formation and decrease bleeding episodes. Qfitlia offers a subcutaneous, once-every-two-month dosing regimen, providing a novel, non-factor therapeutic option for the management of hemophilia.
Small Interfering Ribonucleic Acid (RNA) Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.
View The Full Small Interfering Ribonucleic Acid (RNA) Market Report:
Small Interfering Ribonucleic Acid (RNA) Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
